PMID- 1542546
OWN - NLM
STAT- MEDLINE
DCOM- 19920406
LR  - 20131121
IS  - 0031-3998 (Print)
IS  - 0031-3998 (Linking)
VI  - 31
IP  - 2
DP  - 1992 Feb
TI  - Effect of pentoxifylline on cytokine- and eicosanoid-induced acute pulmonary 
      hypertension in piglets.
PG  - 163-9
AB  - The methylxanthine derivative pentoxifylline (PTF) demonstrates vasodilatory 
      properties in vivo. We tested the hypothesis that PTF infusion would blunt or 
      inhibit tumor necrosis factor-alpha (TNF alpha)-induced and U46,619-induced 
      increases in mean pulmonary artery pressure and pulmonary vascular resistance 
      (PVR) in the neonatal piglet and would do so by altering production of eicosanoid 
      vasoactive mediators. Anesthetized, paralyzed piglets (age 10-29 d) were 
      randomized and treated with a 30-min infusion of TNF alpha alone (n = 13 
      animals), with a combination of TNF alpha plus pretreatment and continuous 
      infusion with PTF (n = 6), or with a combination of U46,619 for 30 min plus 
      pretreatment and continuous infusion of PTF (n = 5). There was no difference in 
      pulmonary or systemic hemodynamic indices between the three groups at baseline. 
      PVR was significantly elevated at 15 min and at 2 h in the TNF alpha-only group. 
      The TNF alpha-induced rise in mean pulmonary artery pressure and PVR was 
      inhibited by the PTF until 2 h, by which time PVR was elevated above baseline and 
      was comparable to the value found in animals treated with only TNF alpha. PTF 
      produced no inhibition in the U46,619-induced elevation of PVR during the 30-min 
      simultaneous treatment. In the PTF + TNF alpha group, mean systemic blood 
      pressure declined to 50% of baseline value (p less than 0.02) by 2 h of age. No 
      significant decline was noted in mean systemic arterial pressure of the TNF 
      alpha-only or the U46,619-treated group.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Truog, W E
AU  - Truog WE
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle 
      98195.
FAU - Gibson, R L Jr
AU  - Gibson RL Jr
FAU - Henderson, W R Jr
AU  - Henderson WR Jr
FAU - Redding, G J
AU  - Redding GJ
FAU - Standaert, T A
AU  - Standaert TA
LA  - eng
GR  - HL-01653/HL/NHLBI NIH HHS/United States
GR  - HL-39157/HL/NHLBI NIH HHS/United States
GR  - RR-00166/RR/NCRR NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pediatr Res
JT  - Pediatric research
JID - 0100714
RN  - 0 (Arachidonic Acids)
RN  - 0 (Prostaglandin Endoperoxides, Synthetic)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 76898-47-0 (15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
MH  - Acute Disease
MH  - Animals
MH  - Animals, Newborn
MH  - Arachidonic Acids/metabolism
MH  - Blood Pressure/drug effects
MH  - Hypertension, Pulmonary/*drug therapy/etiology/physiopathology
MH  - Pentoxifylline/*therapeutic use
MH  - Prostaglandin Endoperoxides, Synthetic
MH  - Pulmonary Circulation/drug effects
MH  - Pulmonary Gas Exchange/drug effects
MH  - Swine
MH  - Tumor Necrosis Factor-alpha
MH  - Vascular Resistance/drug effects
EDAT- 1992/02/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1992/02/11 19:15
PHST- 1992/02/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1992/02/11 19:15 [entrez]
AID - 10.1203/00006450-199202000-00015 [doi]
PST - ppublish
SO  - Pediatr Res. 1992 Feb;31(2):163-9. doi: 10.1203/00006450-199202000-00015.